Evidence map›Paper›PMID 31374996›Full record

ArticleJournal of clinical medicine2019

Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia.

Catia Cillóniz, Cristina de la Calle, Cristina Dominedò, Carolina García-Vidal, Celia Cardozo, Albert Gabarrús, Francesc Marco, Antoni Torres, Alex Soriano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Catia CillónizDepartment of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB) -SGR 911- Ciber de Enfermedades Respiratorias (Ciberes), 08036 Barcelona, Spain.
Cristina de la CalleDepartment of Infectious Disease, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Cristina DominedòDepartment of Anesthesiology and Intensive Care Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Carolina García-VidalDepartment of Infectious Disease, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Celia CardozoDepartment of Infectious Disease, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Albert GabarrúsDepartment of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB) -SGR 911- Ciber de Enfermedades Respiratorias (Ciberes), 08036 Barcelona, Spain.
Francesc MarcoDepartment of Microbiology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Antoni TorresDepartment of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB) -SGR 911- Ciber de Enfermedades Respiratorias (Ciberes), 08036 Barcelona, Spain.
Alex SorianoDepartment of Infectious Disease, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Hospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to analyze the impact of cefotaxime non-susceptibility on the 30-day mortality rate in patients receiving a third-generation cephalosporin for pneumococcal bacteremic pneumonia.

methodsWe conducted a retrospective observational study of prospectively collected data from the Hospital Clinic of Barcelona. All adult patients with monomicrobial bacteremic pneumonia due to

resultsDuring the study period, 721 eligible episodes were identified, and data on the susceptibility to cefotaxime was obtainable for 690 episodes. Sixty six (10%) cases were due to a cefotaxime non-susceptible strain with a 30-day mortality rate of 8%. Variables associated with 30-day mortality were age, chronic liver disease, septic shock, and the McCabe score. Infection by a cefotaxime non-susceptible

conclusionDespite the prevalence of cefotaxime, non-susceptible

Indexed as

bacteremiacefotaximeinfectiousoutcomespneumonia

Identifiers

PMID31374996
PMCPMC6722634
OpenAlexW2952559801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.